Collaborating in the Fight for Health
The Partnership to Fight Infectious Disease (PFID) is a group of patients, providers, community organizations, business and labor groups, and health policy experts working to advance awareness and action on antimicrobial resistance. As an initiative of the Partnership to Fight Chronic Disease, PFID is focusing on the impact of this growing issue on our population and health care system. In particular, we will explore and advance solutions to address the threat of antimicrobial resistance and the need for new antimicrobial treatments.
The COVID-19 crisis has reinforced the critical importance of treatments for infectious disease, as many of the deaths and severe cases involve not only the virus but also superimposed bacterial infections (sometimes hospital acquired “superbugs”) that then ultimately can, and often do, lead to death. Antibiotics and antifungal medicines play a critical role in the treatment of patients suffering from a pandemic, but our supply of effective medicines is dwindling due to antimicrobial resistance (AMR).
According to the Centers for Disease Control and Prevention (CDC), today, more than 2.8 million drug-resistant infections occur in the U.S. each year and more than 35,000 people die as a result. And according to a recent GAO report , this may actually be an underestimate of the problem.
AMR is a threat to all of us, especially those with chronic conditions. Without effective antimicrobial medicines, patients lose not just treatments for serious infections, but they also face significantly increased risks from many medical services that rely upon the effective prevention and treatment of infections.
many other major surgeries like joint replacements
care of preterm infants and immunocompromised patients
other vulnerable patients.
The goals of the PFID include:
Advocating for policy changes that would help activate and support research and development of new antimicrobial treatments to treat drug-resistant infections.
Motivating broad change in the way antimicrobial medicines are prescribed, accessed, consumed, monitored, and paid for.
Reinforcing awareness among all public and private stakeholders about the need for a pipeline of new antimicrobial medicines, the need for access to our existing medicines by providers and patients, the challenges of antimicrobial resistance to the practice of modern medicine, and AMR’s threat to the health of every person.